Document is current
Any future updates will be listed below
-
Authors
Queiroz, Andre Lima
Dantas, Ezequiel https://orcid.org/0000-0003-4934-4632
Ramsamooj, Shakti
Murthy, Anirudh
Ahmed, Mujmmail
Zunica, Elizabeth R. M. https://orcid.org/0000-0002-6850-6054
Liang, Roger J.
Murphy, Jessica
Holman, Corey D. https://orcid.org/0000-0003-1111-7442
Bare, Curtis J.
Ghahramani, Gregory https://orcid.org/0000-0002-7338-6819
Wu, Zhidan
Cohen, David E. https://orcid.org/0000-0001-9827-6926
Kirwan, John P.
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Axelrod, Christopher L. https://orcid.org/0000-0002-1444-8557
Goncalves, Marcus D. https://orcid.org/0000-0002-0784-9248
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Lung Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
American Association for Cancer Research
- License Information
-
More Information
Article History
Received: 31 May 2021
Accepted: 13 July 2022
First Online: 8 August 2022
Competing interests
: L.C.C. is a founder, shareholder, and member of the scientific advisory board of Agios Pharmaceuticals and a founder and former member of the scientific advisory board of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing novel therapies for cancer. L.C.C. has received research funding from Ravenna Pharmaceuticals. M.D.G. reports personal fees from Novartis, Petra Pharmaceuticals, and Bayer. He has received research support from Pfizer Inc. L.C.C. and M.D.G. are inventors on patents unrelated to the scope of the current work. L.C.C. and M.D.G. are co-founders and shareholders in Faeth Therapeutics. Z.W. is a full-time employee of Pfizer Inc. All other authors report no competing interests.
